Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "Vector Purification Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Viral Vector, Type of Purification Technique, Type of ...

The Software Experts analysis reflects a broader trend in creative software toward tools that bridge online accessibility and production readiness. As design output increasingly moves from screen to ...

Demand for adeno-associated viral (AAV) vectors is increasing as more and more cell and gene therapy firms use them to make products. In response, vector suppliers are embracing faster, more efficient ...

SAN FRANCISCO, May 6, 2025 /PRNewswire/ -- The OpenSearch Software Foundation, the vendor-neutral home for the OpenSearch Project, today announced the general availability of OpenSearch 3.0. This ...

The global lentiviral vector CDMO market is set to witness a growth rate of 8% in the next 5 years. Growing demand for gene and cell therapies; expanding pipeline of gene therapy products; ...

The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

This new offer automates preparation, planning and manufacturing to optimize on-demand production flows and reduce material consumption. PARIS, Jan. 23, 2024 /PRNewswire/ -- Lectra supports the ...

Bristol Myers Squibb’s cancer cell therapy Breyanzi. Johnson & Johnson and AstraZeneca’s recombinant COVID-19 vaccines. Novartis’ gene therapy Zolgensma. All of these, plus many others, are united by ...

SAN FRANCISCO--(BUSINESS WIRE)-- Vector Capital, a leading private equity firm specializing in transformational investments in established technology businesses, today announced the successful sale of ...